Cargando…

Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis

OBJECTIVES: In patients with RA treated with (ultra-)low-dose rituximab (RTX), we investigated the association of dosing and timing of RTX on seroconversion after a third coronavirus disease 2019 (COVID-19) vaccination and the persistence of humoral response after a two-dose vaccination. MATERIAL AN...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Togt, Céleste J T, Ten Cate, David F, van den Bemt, Bart J F, Rahamat-Langendoen, Janette, den Broeder, Nathan, den Broeder, Alfons A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452149/ https://www.ncbi.nlm.nih.gov/pubmed/36000861 http://dx.doi.org/10.1093/rheumatology/keac486

Ejemplares similares

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges
por: den Broeder, Alfons A, et al.
Publicado: (2021)

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
por: den Broeder, Alfons A., et al.
Publicado: (2017)

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review
por: Wientjes, Maike H M, et al.
Publicado: (2022)

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
por: van den Bemt, Bart JF, et al.
Publicado: (2011)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
por: Geurts-Voerman, Gerlienke E., et al.
Publicado: (2020)

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
por: den Broeder, Alfons A, et al.
Publicado: (2013)

Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit
por: Ulijn, Evy, et al.
Publicado: (2022)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial
por: Marsman, Diane E., et al.
Publicado: (2022)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
por: van Herwaarden, Noortje, et al.
Publicado: (2015)

Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial
por: Peeters, Iris Rose, et al.
Publicado: (2023)

(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
por: Bolhuis, Thomas E., et al.
Publicado: (2022)

Digital vasculitis in a patient with rheumatoid arthritis: good response on anti-TNF blockade
por: van den Hoogen, F, et al.
Publicado: (2001)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Age-Related Health Hazards in Old Patients with First-Time Referral to a Rheumatologist: A Descriptive Study
por: van Lankveld, W., et al.
Publicado: (2011)

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study
por: Michielsens, Celia A J, et al.
Publicado: (2021)

Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study
por: Bouman, Chantal A M, et al.
Publicado: (2018)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review
por: Tweehuysen, Lieke, et al.
Publicado: (2017)

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
por: Bouman, Chantal A M, et al.
Publicado: (2017)

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
por: Mulder, Michelle L. M., et al.
Publicado: (2020)

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists
por: Lesuis, N, et al.
Publicado: (2016)

The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study
por: Hoogeboom, Thomas J, et al.
Publicado: (2012)

Time to achieve remission determines time to be in remission
por: Schipper, Lydia G, et al.
Publicado: (2010)

Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report
por: Schoffelen, Teske, et al.
Publicado: (2014)

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
por: Michielsens, Celia A. J., et al.
Publicado: (2020)

Electronic Monitoring Feedback for Improving Medication Adherence and Clinical Outcomes in Early Rheumatoid Arthritis: A Randomized Clinical Trial
por: van Heuckelum, Milou, et al.
Publicado: (2021)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
por: Messelink, Marianne A., et al.
Publicado: (2022)

Commentary: Autoimmune diseases in patients with myotonic dystrophy type 2
por: Damen, Manon J., et al.
Publicado: (2022)

Why so far ahead? Climbing the participation ladder in public health foresight
por: Den Broeder, L, et al.
Publicado: (2023)

Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients
por: Damen, Michelle S. M. A., et al.
Publicado: (2018)

What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis
por: Messelink, Marianne A, et al.
Publicado: (2023)

Non-pharmacological care for patients with generalized osteoarthritis: design of a randomized clinical trial
por: Hoogeboom, Thomas J, et al.
Publicado: (2010)

Feasibility and potential effectiveness of a non-pharmacological multidisciplinary care programme for persons with generalised osteoarthritis: a randomised, multiple-baseline single-case study
por: Hoogeboom, Thomas J, et al.
Publicado: (2012)

Effectiveness and cost‐effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials
por: van Wissen, Maria. A. T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2m4iefa3fjd3ur5l2efvad9h85